Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. develops healthcare technology for chronic low back pain through Nociscan, a cloud-based SaaS platform that uses magnetic resonance spectroscopy, biomarkers, signal processing and augmented intelligence algorithms to help physicians evaluate painful and nonpainful lumbar discs.
Company news commonly covers Nociscan adoption, clinical-site additions, commercial agreements with spine practices and academic medical centers, reimbursement activity, intellectual-property updates for AI-enabled workflows, and operating results. Updates also include capital actions and governance items tied to Aclarion’s Nasdaq-listed common stock and warrants.
Aclarion (Nasdaq: ACON, ACONW) added Lanman Spinal Neurosurgery in Beverly Hills as the first private-practice site for its 300-patient CLARITY randomized trial of Nociscan for discogenic chronic low back pain. The trial's primary endpoint is 12-month change in 100mm VAS Back; early interim results are expected to be publicly disclosed in Q4 2026.
Nociscan is described as a SaaS MR spectroscopy solution that quantifies chemical biomarkers and is reported to show a 97% surgical success rate when all Nociscan-positive discs are treated.
Aclarion (Nasdaq: ACON, ACONW) granted an inducement stock option to Daniel Keefe, its new Commercial Director, Western U.S., to purchase 17,000 shares on May 5, 2026. The option exercise price is $3.20 per share, equal to the closing price on the grant date.
One-fourth vests after one year; remaining options vest monthly over three years. The option term is ten years and was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Mr. Keefe joining the company.
Aclarion (Nasdaq: ACON, ACONW) announced a second commercial agreement with Weill Cornell Medicine to expand clinical use of its Nociscan platform in a prospective randomized trial led by Roger Härtl, MD (IRB Protocol No. 24-09027977). The study will assess lumbar microdiscectomy with or without intradiscal bone marrow aspirate concentrate (BMAC) over two years, measuring patient-reported outcomes, intervertebral disc health, and pain biomarkers. Aclarion says Nociscan quantifies chemical biomarkers linked to disc pain and reports a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated.
Aclarion (NASDAQ:ACON) reported Q1 2026 results showing accelerating adoption of its Nociscan platform. Key metrics: scan volume +196% YoY and +64% sequential. The company holds $19.0M cash, no debt, 64 issued/pending patents, and announced a $2.5M share repurchase.
Clinical and commercial catalysts include payer reimbursements in the U.K., seven ongoing trials, and an interim CLARITY readout expected for public disclosure in late 2026. Cash runway is projected into H2 2027 on current plans.
Aclarion (Nasdaq: ACON, ACONW) appointed Daniel Keefe as Commercial Director, Western U.S., to lead regional commercial expansion and support continued adoption of Nociscan.
The hire accompanies reported triple-digit utilization growth and cites a 97% surgical success rate when all Nociscan-positive discs are treated, highlighting clinical uptake and commercial momentum.
Aclarion (Nasdaq: ACON) announced a $2.5 million stock repurchase program authorized by its board on April 22, 2026. The company expects to execute repurchases over the next 12 months, funded with existing cash and cash equivalents, subject to market conditions and legal rules.
As of March 31, 2026, Aclarion reported approximately $19.0 million in cash and cash equivalents and said the cash runway supports operations through near-term milestones, including the CLARITY randomized trial.
Aclarion (Nasdaq: ACON, ACONW) announced issuance of U.S. Patent #12,601,803 on April 16, 2026 for a machine learning–based system to analyze magnetic resonance spectroscopy (MRS) data. The patent covers AI-driven model training, automated data quality controls, and biomarker extraction within the cloud-based Nociscan platform.
The filing expands Aclarion's intellectual property to 64 issued and pending patents worldwide and is described as enabling scale, faster reports, reduced manual reviews, and more consistent outputs across imaging systems.
Aclarion (NASDAQ: ACON) received a Diamond Pinnacle Award for AI Innovation in Clinical Decision AI on April 14, 2026, recognizing its Nociscan MR spectroscopy–based SaaS platform for identifying biochemical markers of discogenic chronic low back pain.
The company cites a 97% surgical success rate when all Nociscan-positive discs are treated and notes global prevalence estimates of 266 million people with degenerative spine disease and low back pain.
Aclarion (Nasdaq: ACON) announced a commercial agreement with Weill Cornell Medicine to bring Nociscan to Weill Cornell and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. A subset of spine patients in an IRB-approved trial (Protocol No. 22-06024915) will be eligible for Nociscan to help identify discogenic low back pain.
The study investigates dose and quantity of concentrated bone marrow aspirate (BMAC) for osteoarthritis and degenerative disc disease, with Nociscan used alongside other diagnostics.
Aclarion (Nasdaq: ACON) released a new physician video (April 7, 2026) featuring Mr. John Sutcliffe of The London Spine Clinic demonstrating real-world use of Nociscan to evaluate chronic low back pain.
Nearly 100 Nociscans have been performed at The London Clinic; Nociscan uses MR spectroscopy and proprietary signal processing to identify chemical biomarkers linked to disc pain. According to the company, clinical data showed up to 97% surgical success when all Nociscan-positive discs are treated, and the video signals growing physician adoption at a leading international center.